
Selecta Biosciences SELB
Annual report 2025
added 03-09-2026
Selecta Biosciences Interest Expense 2011-2026 | SELB
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Selecta Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.01 M | 606 K | 2.83 M | 3.03 M | 2.84 M | 1.56 M | 1.52 M | 1.49 M | 1.21 M | 1.25 M | 948 K | 552 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.03 M | -2.01 M | 1.32 M |
Quarterly Interest Expense Selecta Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -5 K | - | - | 250 K | 292 K | 508 K | - | 253 K | 245 K | 808 K | - | 802 K | 715 K | 707 K | - | 711 K | 711 K | 711 K | - | 365 K | 205 K | 273 K | - | 388 K | 400 K | 396 K | - | 384 K | 365 K | 350 K | - | 268 K | 279 K | 300 K | - | 311 K | 310 K | 310 K | - | 334 K | 330 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 808 K | -5 K | 409 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Allakos
ALLK
|
8 K | - | - | $ 28.6 M | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
AlloVir
ALVR
|
1.44 M | - | 4.14 % | $ 49.1 M | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
1.82 M | $ 22.67 | 1.66 % | $ 3.76 B | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Applied Therapeutics
APLT
|
-27 K | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | ||
|
Atreca
BCEL
|
3 K | - | -11.76 % | $ 5.79 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-93 K | - | -2.5 % | $ 5.88 M | ||
|
BioNTech SE
BNTX
|
14.2 M | $ 102.06 | - | $ 27.2 B | ||
|
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | ||
|
Aquestive Therapeutics
AQST
|
6.55 M | $ 4.09 | -0.24 % | $ 437 M | ||
|
Arcutis Biotherapeutics
ARQT
|
443 K | $ 23.29 | -0.56 % | $ 2.96 B | ||
|
Autolus Therapeutics plc
AUTL
|
36.7 M | $ 1.48 | 4.23 % | $ 394 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
227 K | $ 2.91 | 0.34 % | $ 4.79 M | ||
|
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
bluebird bio
BLUE
|
16.4 M | - | - | $ 546 M | ||
|
Cara Therapeutics
CARA
|
7.16 M | - | -3.03 % | $ 260 M | ||
|
CASI Pharmaceuticals
CASI
|
2.9 K | - | - | $ 35.4 M | ||
|
BioXcel Therapeutics
BTAI
|
-3.52 M | $ 1.06 | -2.75 % | $ 12.9 M | ||
|
ChemoCentryx
CCXI
|
2.7 M | - | - | $ 3.74 B | ||
|
Cabaletta Bio
CABA
|
2 M | $ 2.86 | -1.72 % | $ 287 M | ||
|
Cidara Therapeutics
CDTX
|
5.81 M | - | - | $ 1.41 B | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M |